Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pancreatic cancer heterogeneity and response to Mek inhibition.

Oncogene - 5 Oct 2017

Pedersen K, Bilal F, Bernadó Morales C, Salcedo M T, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras M-J, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J

Abstract excerpt

Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer (PC) has not yet translated into effective treatments. Many promising drugs have failed in the clinic, highlighting the need for better preclinical models to assess drug efficacy and characterize mechanisms of resistance. Using different experimental models, including patient-derived xenografts (PDXs), we gauged the efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Mitogen-Activated Protein Kinase Kinases

Share to Paclitaxel

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28581516
DOI: 10.1038/onc.2017.174

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pancreatic cancer heterogeneity and response to Mek inhibition.PMID 28581516Read ↗

The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.Semantic proximity Read ↗

Tumor Heterogeneity in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.Semantic proximity Read ↗

An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.Semantic proximity Read ↗

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cellsSemantic proximity Read ↗

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.Semantic proximity Read ↗

Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative ProteomicsSemantic proximity Read ↗

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.Semantic proximity Read ↗

Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.